Mather Group’s Cytokinetics CYTK Stock Holding History

Mather Group’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$6.26K	Buy	+95	New	+$7.24K	﹤0.01%	1770

Other funds holding CYTK

Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return

E. Ohman J:or Asset Management Stockholm, Sweden $4.47B AUM 27.58% 1-Year Est. Return

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

Yousif Capital Management Bloomfield Hills, Michigan $8.87B AUM 34.1% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Mather Group's CYTK Position: Q3 2026 in Review

Mather Group opened a new position in Cytokinetics (CYTK) in Q3 2026: 95 shares worth $6.26K. The stake represents ﹤0.01% of the portfolio and ranks #1770 among its holdings.

60 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

Mather Group held 95 shares of Cytokinetics worth $6.26K as of Q3 2026.
Cytokinetics was a new Mather Group position in Q3 2026.
Cytokinetics made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #1770 holding.
60 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.